What HAVN Life Sciences does

HAVN Life Sciences is a Canadian biotechnology company founded in 2020 and headquartered in Vancouver, British Columbia, that operates two divisions focused on psychedelic medicine and natural health products. Its HAVN Labs division develops an end-to-end GMP supply chain for naturally derived psychedelic compounds — primarily psilocybin — supplying standardized APIs and formulations to academic institutions and clinical trial operators; the company was among the first to receive Health Canada permission to work with psilocybin (2020) and subsequently obtained Licensed Dealer status (2021). Its HAVN Retail division sells a line of functional mushroom and plant extract products (Lion's Mane, Cordyceps, Reishi, Chaga) through direct-to-consumer e-commerce, retail distribution, and white-label contract manufacturing, with additional packaging and manufacturing capacity acquired via the 2021 purchase of GCO Packaging and Manufacturing.

The company's underlying technology centers on proprietary psilocybin extraction and analytical protocols developed under Health Canada exemption, combined with a planned psilocybin cultivation operation in Jamaica and a research facility build-out in Vancouver. Its go-to-market blends enterprise field sales to academic and clinical research customers with B2B white-label and distribution partnerships (including Woke Pharmaceuticals in Australia, MPB Group, and Atman Retreats) alongside a community-led motion through veteran-facing organizations (Heroic Hearts Project, Westwood Institute) and a research collaboration with the University of British Columbia's Institute for Veterans Education and Transition focused on treatment-resistant PTSD.

Revenue mechanics span one-time product sales (natural health products), per-transaction fees (psychedelic compound supply to researchers), and professional services (white-label contract manufacturing), supplemented by capital raised through convertible debenture financing from institutional investors such as Alpha Blue Ocean. The company is publicly listed on the CSE (HAVN), OTC Markets (HAVLF), and Frankfurt Stock Exchange (5NP), but operates with a 1-10 employee headcount and faced a Management Cease Trade Order from the BCSC in 2023 due to delayed financial filings.

Name

HAVN Life Sciences

Legal name

HAVN Life Sciences Inc.

Website

https://havnlife.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

HAVN Life Sciences is a Vancouver-based biotech operating two divisions: HAVN Labs, which supplies GMP psilocybin APIs to academic and clinical researchers, and HAVN Retail, which sells functional mushroom and plant extract natural health products via e-commerce, retail, and white-label channels.

Ownership category

akta.pro rank

Product category

Biotechnology - Psychedelic Compounds & Natural Health Products

NAICS

Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Herbal & Botanical Supplements (CRADAGAD)

akta.pro secondary industry

Healthy Aging & Cognitive Support Supplements (CRADAGAM)

Keywords

• Psilocybin extraction
• Psychedelic compounds
• Natural health products
• GMP psychedelic supply
• Functional mushroom extracts

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Natural Health Products: Sale of high-quality mushroom and plant extracts including Lion's Mane, Cordyceps, Reishi, and Chaga that support immune function, reduce inflammation, and promote healthy lifestyle
2. Psychedelic Compound Supply: Supply of standardized psychedelic compounds and APIs to academic institutions for clinical trials, pending Licensed Dealer status approval from Health Canada
3. White Label Manufacturing: Contract manufacturing and white-label production services for distribution partners, including product formulation and manufacturing at scale
4. Financing Arrangements: Convertible debenture financing from institutional investors including Alpha Blue Ocean, with proceeds for general working capital purposes

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

HAVN Life Sciences is a biotechnology company developing an end-to-end GMP psychedelic supply chain for clinical researchers through its HAVN Labs division, providing standardized psilocybin extraction, formulation, and delivery of compounds and APIs for academic institutions and clinical trials. Through its HAVN Retail division, the company sells natural health products including functional mushroom and plant extracts (Lion's Mane, Cordyceps, Reishi, Chaga) directly to health-conscious consumers via e-commerce and retail channels. The company also offers white-label contract manufacturing and microdosing formulations targeting mental health applications including PTSD.

Product overview

HAVN Life Sciences operates as a biotechnology company with two main divisions: HAVN Labs, which develops psychedelic supply chain infrastructure for clinical researchers through extraction, formulation and delivery of GMP-certified psychedelic compounds including psilocybin; and HAVN Retail, which offers a line of natural health products featuring mushroom and plant extracts. The company is pursuing standardized extraction of psychoactive compounds and developing microdosing formulations for mental health applications, particularly focused on veterans and PTSD research.

Differentiator

Problem solved

Functional benefit

Brands

• HAVN Labs: Research division focused on psychedelic supply chain for clinical researchers, including extraction, formulation and delivery of psychedelics for research purposes.
• HAVN Retail

Products and services

• HAVN Labs Psychedelic Supply Chain Research division developing an end-to-end psychedelic supply chain for clinical researchers, including GMP-certified extraction, formulation, and delivery of naturally derived psychedelic compounds (psilocybin) and APIs for academic institutions and clinical trials.
• HAVN Retail Natural Health Products Natural health product line offering high-quality mushroom and plant extracts including Lion's Mane, Cordyceps, Reishi, and Chaga that help boost immune function, reduce inflammation, and support a healthy lifestyle. Distributed direct-to-consumer via e-commerce and through retail and distribution partner channels.
• Psilocybin Compound Supply GMP naturally derived psychedelic compounds isolated and extracted from psychedelic mushrooms for use in clinical trials and as active pharmaceutical ingredients (APIs) for product development. Supplied to academic institutions and clinical trial operators under Licensed Dealer authority.
• White-Label Contract Manufacturing Contract manufacturing and white-label production services for distribution partners, including product formulation and manufacturing at scale for psychedelic and natural health products.
• Microdosing Formulations

Quantifiable outcome

• Global psychedelic drugs market projected to reach $5.16 billion by 2034 with 12.27% CAGR
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Heroic Hearts ProjectcoreStrategic or Co-development Partner · 1 January 2020Nonprofit connecting military veterans struggling with trauma to psychedelic therapy options. HAVN provides funding for support services and low-dosage psilocybin for veteran studies, with collaboration on treatment protocol development.
• University of British Columbia (Institute for Veterans Education and Transition)coreStrategic or Co-development Partner · 1 January 2020Research partnership with UBC's Veterans Friendly Campus Initiative to launch research project where veterans take leadership in creating protocols and best use processes for alternative medicines. Phase 1 research examining veterans' current use and perceptions of psilocybin for mental health disorders.
• Westwood InstituteminorStrategic or Co-development PartnerVeterans organization providing funding support and low-dosage psilocybin access for future veteran studies addressing PTSD and trauma-related disorders.
• MPB Group IncminorChannel Partner/ Reseller/ DistributorSupply agreement partnership for distribution of HAVN Life products.
• Atman RetreatsminorChannel Partner/ Reseller/ DistributorSupply agreement partnership for distribution of psychedelic compounds and products.
• Woke PharmaceuticalsminorChannel Partner/ Reseller/ DistributorDistribution partner in Australia receiving first white label order for psychedelic products.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Compass Pathways: Clinical-stage mental-health company developing psilocybin therapy for treatment-resistant depression. Directly comparable as a psilocybin-focused developer leveraging clinical research infrastructure, though larger and Nasdaq-listed.
• Mind Medicine (MindMed): Public psychedelic-medicine developer advancing psilocybin and MDMA programs for mental-health disorders. Comparable as a publicly traded psychedelic biotech with overlapping clinical indications and supply-chain considerations.
• Cybin Inc. Public psychedelic therapeutics company developing psilocybin-based treatments for depression and addiction. Comparable as a Canadian-listed (NEO) peer pursuing proprietary psilocybin formulations and clinical research.
• atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health. Comparable as a public peer operating a portfolio of psychedelic programs with similar regulatory and clinical-trial risk profile.
• Numinus Wellness: Canadian mental-health company operating psychedelic-assisted therapy clinics and psilocybin research programs. Comparable as a Vancouver-based public peer with overlapping psilocybin supply and clinical-research ambitions.
• GH Research: Clinical-stage biopharmaceutical company developing mebufotenin (5-MeO-DMT) therapies for treatment-resistant depression. Comparable as a psychedelic API developer targeting similar clinical indications and end-patient populations.

Emerging players

• Field Trip Health: Operator of psychedelic-assisted therapy clinics and developer of novel psychedelic compounds. Partial overlap on clinical-research infrastructure and mental-health positioning, with a clinic-led business model rather than supply-chain focus.
• NextLeaf Solutions: Public cannabis extraction company with proprietary IP around cannabinoid oil processing. Comparable as a publicly traded Canadian extraction-technology peer whose core IP and team overlap (Director Dr. Ivan Casselman was previously with NextLeaf).

Broad incumbents

• Jamieson Wellness: Large Canadian manufacturer and distributor of natural health products, vitamins, and supplements. Comparable as the dominant incumbent in the B2C mushroom-extract and supplement category where HAVN Retail competes.

Regional players

• Woke Pharmaceuticals: Australian psychedelic-products distributor that received HAVN's first international white-label order in 2022. Comparable as a downstream distribution partner in a separate geography, illustrating the channel model rather than direct competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/HavnLife
• Facebookfacebook.com/havnlife
• LinkedInlinkedin.com/company/havnlife
• Instagraminstagram.com/havn.life

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HAVN Life Sciences